
Spēles mainītājs. Vai CRISPR terapijas var pacelties?
In recent years, CRISPR Therapeutics has faced a tough market, with its stock struggling to gain traction. Despite the setbacks, there are promising updates that could change the company’s future trajectory. Paplašinot horizontus ar Casgevy CRISPR Therapeutics, sadarbojoties ar Vertex Pharmaceuticals, ir